Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03494179
Recruitment Status : Active, not recruiting
First Posted : April 11, 2018
Last Update Posted : July 16, 2020
Sponsor:
Information provided by (Responsible Party):
Beijing InnoCare Pharma Tech Co., Ltd.

Brief Summary:
The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.

Condition or disease Intervention/treatment Phase
Mantle Cell Lymphoma Drug: ICP-022 Phase 1 Phase 2

Detailed Description:

Part I: PK/PD and safety evaluation -Two regimens of ICP-022 (High dose QD and low dose BID) were designed for assessment of safety, as well as PK/PD profiles. The recommended dose of phase II clinical study will be determined according to the Part I results.

Part II: Dose expansion -Anti-tumor effects of ICP-022 in Chinese patients with R/R MCL will be evaluated in approximately 80 subjects. The recommended Phase 2 dose will be used in the Part II.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Actual Study Start Date : April 2, 2018
Estimated Primary Completion Date : December 31, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: High Dose of ICP-022
Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
Drug: ICP-022
The drug product is a white, round, uncoated tablet.

Experimental: Low Dose of ICP-022
Two regimens of ICP-022 (High dose QD and low dose BID) are designed for study Part I to determine RP2D which will be used in Part II to further evaluate the preliminary anti-tumor effects of ICP-022 in Chinese subjects with R/R MCL.
Drug: ICP-022
The drug product is a white, round, uncoated tablet.




Primary Outcome Measures :
  1. overall response rate (ORR) [ Time Frame: Up to 3 years ]
    The efficacy measured by overall response rate (ORR) in Part II according to the 2014 International Working Group NHL


Secondary Outcome Measures :
  1. Occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria in Part I [ Time Frame: Up to 3 years ]
    The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria in Part I

  2. time to progression (TTP) [ Time Frame: Up to 3 years ]
    The efficacy measured by time to progression (TTP) in Part II

  3. progression free survival (PFS) [ Time Frame: Up to 3 years ]
    The efficacy measured by progression free survival (PFS) in Part II

  4. overall survival (OS) [ Time Frame: Up to 3 years ]
    The efficacy measured by overall survival (OS) in Part II

  5. Area under the concentration time curve up to the time "t" (AUC(0-t)) [ Time Frame: up to 4 weeks ]
    Area under the concentration time curve up to the time "t" (AUC(0-t)) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.

  6. The percent of target occupancy [ Time Frame: up to 4 weeks ]
    PBMC from individual subject before and after dosing will be collected and the target occupancy will be determined by ELISA. The percent of target occupancy will be compared descriptively.

  7. Maximum plasma drug concentrations (Cmax) [ Time Frame: up to 4 weeks ]
    Individual plasma concentrations of ICP-022 will be measured and Cmax will be calculated with noncompartmental analysis using WinNonlin.

  8. Time of maximum plasma drug concentrations (Tmax) [ Time Frame: up to 4 weeks ]
    Time of maximum plasma drug concentrations (Tmax) of ICP-022 will be recorded.

  9. Apparent half-life for designated elimination phases (t½) [ Time Frame: up to 4 weeks ]
    Apparent half-life for designated elimination phases (t½) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.

  10. Area under the concentration time curve up to the last data point above LOQ (AUC(last)) [ Time Frame: up to 4 weeks ]
    Area under the concentration time curve up to the last data point above LOQ (AUC(last)) of ICP-022 will be measured and calculated with noncompartmental analysis using WinNonlin.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women between 18 and 75 years old
  • Histologically confirmed mantle cell lymphoma (MCL), with either t(11;14) by cytogenetics and/or cyclin D1 overexpression by immunohistochemistry (IHC)
  • Subjects with refractory or relapsed mantle cell lymphoma who has received at least 1 but no more than 4 prior therapies for MCL
  • At least one measurable tumor of greater than 1.5 centimeter in long axis by contrast-enhanced CT/MRI
  • ECOG performance status of 0-2
  • Documented failure to achieve at least partial response (PR) or documented disease progression after response to, the most recent treatment regimen.
  • Subjects who meet the following laboratory parameters:

    1. Absolute neutrophil count (ANC) ≥ 1.5×109/L Platelet count ≥ 75×109/L, independent of growth factor support within 7 days of the first dose with study drug, Hemoglobin ≥ 80 g/L; ANC ≥ 1.0×109/L, Platelet count ≥ 50×109/L if bone marrow involvement
    2. Total bilirubin ≤ 2× ULN; AST or ALT ≤ 2.5 ULN; Creatinine clearance ≥ 30ml/min; Amylase ≤ ULN and Lipase ≤ ULN
    3. International normalized ratio (INR) ≤ 1.5 ULN and activated partial thromboplastin time (APTT) ≤ 1.5 ULN
  • Life expectancy ≥ 4 months
  • Able to provide signed written informed consent

Exclusion Criteria:

  • History of other active malignancies within 5 years of study entry, unless cured without evidence of relapse or metastasis
  • Current or history of lymphoma involved central nervous system
  • Prior corticosteroids (at dosages equivalent to prednisone > 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, radiation therapy, or antibody based therapies or anti-cancer TCM within 4 weeks of the start of study drug.
  • Non-hematological toxicity must recover to ≤ Grade 1 from prior anti-cancer therapy
  • Current clinically significant cardiovascular disease including:

    • Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%
    • Primary cardiomyopathy
    • Clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male)
    • Uncontrolled hypertension
  • Known active bleeding within 2 months of screening or currently taking anticoagulant/antiplatelet drugs
  • Urine protein ≥ 2+ and quantitation ≥ 2g/24hours
  • History of deep vein thrombosis or pulmonary embolism
  • Disease significantly affecting gastrointestinal function such as dysphagia, chronic diarrhea, intestinal obstruction, or resection of the stomach
  • Allogeneic stem cell transplant within 6 months prior to first dose of study drug or related active infection
  • Major surgery within 6 weeks of screening, except for diagnostic test or vascular access setup
  • Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection
  • Any history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe lung function impairment
  • Prior exposure to a BTK inhibitor,BCR pathway ingibitor(such as PI3K, SYK) or BCL-2 kinase inhibitor
  • Suitable and ready for allogeneic stem cell transplant
  • Inability to comply with study procedures
  • Drug abuser or alcoholics
  • Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children
  • Requires treatment with moderate or strong cytochrome P450 family 3, subfamily A (CYP3A) inhibitors or strong CYP3A inducers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03494179


Locations
Show Show 31 study locations
Sponsors and Collaborators
Beijing InnoCare Pharma Tech Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Jun Zhu, PhD Beijing Cancer Hospital
Layout table for additonal information
Responsible Party: Beijing InnoCare Pharma Tech Co., Ltd.
ClinicalTrials.gov Identifier: NCT03494179    
Other Study ID Numbers: ICP-CL-00102
First Posted: April 11, 2018    Key Record Dates
Last Update Posted: July 16, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin